HYBRID EVENT: Join us in person in Rome, Italy or attend virtually from anywhere.

13th Edition of International Conference on

Neurology, Brain Health & Neurological Disorders

June 24-26, 2027 | Rome, Italy

Neuroprotective Agents

Neuroprotective Agents

Neuroprotective agents refer to compounds and drugs that are used to protect neurons and other cells of the nervous system from damage and diseases. The concept of neuroprotection was introduced in the 1980s and has since become an increasingly important field of research in neuroscience. Neuroprotection is a complex process that involves a number of different factors, such as the prevention of neurotoxin accumulation, the promotion of neuronal survival or regeneration, the inhibition of apoptosis, and the control of inflammatory cascades. Neuroprotection is thought to be triggered by a variety of different stimuli, including oxidative stress, glutamate excitotoxicity, and calcium dysregulation. One approach to protection of the nervous system is to target the neurotoxins, such as those secreted by activated glia. Inhibition of excitotoxicity can be reached by both antagonizing glutamate receptors or blocking its receptors from binding the agonists. Many drugs have been developed that target neurological receptors, reducing the influx of calcium and reducing intracellular calcium levels. Another approach is to target cell survival and regenerative pathways. Neurotrophic factors such as nerve growth factor (NGF) are able to promote neurogenesis and neuronal survival. In addition, antioxidants are proposed to reduce oxidative damage and perceived age-related diseases of the CNS. The use of both natural and synthetic compounds, such as vitamins, minerals, plant extracts, and herbal derivatives, has been proposed in the treatment of neurodegenerative diseases. It is important to understand that not all treatments are equal and that careful selection is necessary to find an effective and safe neuroprotective agent. It is also important to consider potential side effects of any of the agents and whether they will hamper the therapeutic effect. Ultimately, it is up to the patient and the healthcare provider to decide which neuroprotective agent is best for the given situation.

Committee Members
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - Yong Xiao Wang

Yong Xiao Wang

Albany Medical College, United States
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - Sid O Bryant

Sid O Bryant

Texas College of Osteopathic Medicine and University of North Texas Health Science Center Fort Worth, United States
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - W S El Masri

W S El Masri

Keele University, United Kingdom
Neurology 2027 Speakers
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - Luiz Moutinho

Luiz Moutinho

University of Suffolk, United Kingdom
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - Bernd Blobel

Bernd Blobel

University of Regensburg, Germany
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - Salvador Ventura

Salvador Ventura

Autonomous University of Barcelona, Spain
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - Zhenhuan Liu

Zhenhuan Liu

Guangzhou University of Chinese Medicine, China

Submit your abstract Today

Watsapp